[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-359322-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-359322-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","refining-tumor-mutational-burden-as-a-predictive-biomarker-for-pembrolizumab-a-real-world-analysis-in-japanese-patients","Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab - A Real-World Analysis in Japanese Patients","","Tumor mutational burden (TMB) serves as a key biomarker for predicting response to immune checkpoint inhibitors, yet its real-world predictive accuracy—especially in Asian populations—remains limited. This analysis used Japanese real-world data from 63,952 patients in the C-CAT database and evaluated pembrolizumab outcomes in 1,899 patients who received one of three comprehensive genomic profiling tests. Patients were stratified by TMB values (TMB-high ≥10 vs TMB-low \u003C10 mut/Mb).",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/refining-tumor-mutational-burden-as-a-predictive-biomarker-for-pembrolizumab-a-real-world-analysis-in-japanese-patients/359322/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/refining-tumor-mutational-burden-as-a-predictive-biomarker-for-pembrolizumab-a-real-world-analysis-in-japanese-patients/359322.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How was TMB defined and used to classify patients in this study?","Question",{"text":63,"@type":64},"Patients were classified as TMB-high when the reported TMB was ≥10 mutations per megabase and TMB-low when it was \u003C10 mutations per megabase.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What real-world data source and population were analyzed?",{"text":68,"@type":64},"The study used real-world data from 63,952 patients registered in the C-CAT database and focused pembrolizumab efficacy in 1,899 Japanese patients who had undergone comprehensive genomic profiling.",{"name":70,"@type":61,"acceptedAnswer":71},"Did response differ around the TMB threshold, and how were hotspot mutations handled?",{"text":72,"@type":64},"Patients with borderline TMB values (10 to less than 13 mut/Mb) showed more modest responses, and objective response improved when hotspot mutations were excluded from the TMB calculation, suggesting better predictive performance near the threshold.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},359322,1791075421,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":115,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Cancer Science  \nORIGINAL ARTICLE  OPEN ACCESS   \nGenetics, Genomics, and Proteomics  \nRefining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients  \nTomoyo Yasuda1 | Mio Yumura1 | Azusa Hamasaki1 | Tongyi Fei1  | Takashi Kubo2,3 | Hitoshi Ichikawa2,4 | Takashi Kohno5,6  | Kuniko Sunami3,5   \n1Sysmex Corporation, Kobe, Hyogo, Japan | 2Department of Clinical Genomics, National Cancer Center Research Institute, Tokyo, Japan | 3Department of Laboratory Medicine, National Cancer Center Hospital, Tokyo, Japan | 4Department of Analytical Pathology, National Cancer Center Research Institute, Tokyo, Japan | 5Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan | 6Division of Translational Genomics, National Cancer Center Exploratory Oncology Research and Clinical Trial Center, Tokyo, Japan  \nCorrespondence: Kuniko Sunami ([ksunami@ncc.go.jp](ksunami@ncc.go.jp))  \nReceived: 8 December 2025 | Accepted: 5 January 2026  \nKeywords: comprehensive genomic profiling | immune checkpoint inhibitors | precision oncology | real-world data analysis | tumor mutation burden  \nABSTRACT  \nTumor mutational burden (TMB) is a key biomarker for predicting the response to immune checkpoint inhibitors (ICIs). However, its predictive accuracy in real-world clinical practice, particularly in Asian populations, remains inadequately evaluated. We addressed this issue by analyzing real-world data from 63,952 patients registered in the Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, which integrates genomic and clinical information from Japanese patients with various advanced solid tumors. We assessed the therapeutic efficacy of pembrolizumab in 1899 patients who underwent one of three comprehensive genomic profiling tests: FoundationOne CDx, the OncoGuide NCC Oncopanel System, or the GenMine TOP Cancer Genome Profiling System. Based on the reported TMB values, patients were classified as TMB-high (≥10 mutations per megabase) or TMB-low (\u003C 10 mutations per megabase). The objective response rate (ORR) among 946 TMB-high patients exceeded 30% and was significantly higher than that observed in 953 TMB-low patients (16.8%, p \u003C 0.001) . Notably, patients with borderline TMB values (10 to less than 13 mutations per megabase) exhibited relatively modest responses (20.8%) . The ORR improved when hotspot mutations were excluded from the TMB calculation, suggesting that this adjustment enhances the predictive accuracy of TMB. These findings support the clinical utility of TMB as a biomarker for predicting ICI response in routine oncology practice. In particular, excluding hotspot mutations from TMB calculations may improve response prediction in patients whose TMB values are near the threshold.  \n1 | Introduction  \nCancer immunotherapy with immune checkpoint inhibitors (ICIs) has become a major treatment modality for various cancers  \n[1–3] . Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase (mut/Mb) in genomic regions analyzed by next-generation sequencing, is widely recognized as a key biomarker for predicting the response to ICIs  \n\n| Abbreviations: 95% CI, 95% confidence interval; C-CAT, Center for Cancer Genomics and Advanced Therapeutics; CGP, comprehensive genomic profiling; CR, complete response; F1CDx, FoundationOne CDx; ICIs, immune checkpoint inhibitors; MAF, minor allele frequency; MSI, microsatellite instability; NOP, OncoGuide NCC Oncopanel System; ORR, objective response rate; PD, progressive disease; post-CGP, post-comprehensive genomic profiling treatment; PR, partial response; pre-CGP, pre-comprehensive genomic profiling treatment; SD, stable disease; SNP, single-nucleotide polymorphisms; TMB, tumor mutational burden; TOP, GenMine TOP Cancer Genome Profiling System; WES, whole exome sequencing. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial Licen","cbCaikzPi1kQ7t47","https://ap.wps.com/l/cbCaikzPi1kQ7t47","pdf",1994297,"English","# Introduction\n## Tumor mutational burden as an immunotherapy biomarker\n## Real-world evidence gap in Asian populations\n## Technical factors affecting TMB estimation","[{\"question\":\"How was TMB defined and used to classify patients in this study?\",\"answer\":\"Patients were classified as TMB-high when the reported TMB was ≥10 mutations per megabase and TMB-low when it was \\u003c10 mutations per megabase.\"},{\"question\":\"What real-world data source and population were analyzed?\",\"answer\":\"The study used real-world data from 63,952 patients registered in the C-CAT database and focused pembrolizumab efficacy in 1,899 Japanese patients who had undergone comprehensive genomic profiling.\"},{\"question\":\"Did response differ around the TMB threshold, and how were hotspot mutations handled?\",\"answer\":\"Patients with borderline TMB values (10 to less than 13 mut/Mb) showed more modest responses, and objective response improved when hotspot mutations were excluded from the TMB calculation, suggesting better predictive performance near the threshold.\"}]","Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab - A Real-World Analysis in Japanese Patients | PDF",1790136688,23,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6685481acadb793032c940d8f5833336.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/857c1a3af3d68cfc6c7985736f32a524.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bd50bb9e39ffbb21eaa21f95c48aed78.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e06c8aef926766d2b869ebc9e77c8e5d.webp",980,1287]